Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.
Attralus has raised $56.0M in total funding. The most recent round was Series B. The last funding was announced in February 2024.
Attralus's investors include Vivo Capital, Samsara BioCapital, Redmile Group, Bristol-Myers Squibb, Janus Henderson Investors.
Attralus is headquartered in San Francisco, United States.
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.
Attralus is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Attralus — Funding & Investors." VCBacked, February 6, 2024, https://www.vcbacked.co/company/attralus. Accessed July 20, 2026.
VCBacked. (2024). Attralus — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/attralus
{{cite web |title=Attralus — Funding & Investors |url=https://www.vcbacked.co/company/attralus |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated